Drugs / 2-(1-Hydroxyethyl)-2-Devinylpyropheophorbide-a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00060268 | Jan 1997 → Sep 2003 | esophageal cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-(1-Hydroxyethyl)-2-Devinylpyropheophorbide-a | “A Phase I/II Trial for Treatment of Obstructive Esophageal Tumors by Photodynamic Therapy (PDT) Using 2-(1-Hydroxyethyl)-2-Devinylpyropheophorbide-a (HPPH)” NCT00060268 ↗ |
| Known as | HPPH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00060268 ↗ |
| Route | Intravenous | “Patients receive HPPH IV over 1 hour on day 1.” NCT00060268 ↗ |